Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | RFA AR 20 001

Opportunity Information: Apply for RFA AR 20 001

The NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) funding opportunity RFA-AR-20-001, titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)," supports time-sensitive, hypothesis-driven mechanistic research that can be added onto an already funded and actively running clinical project. The central idea is to take advantage of existing patient cohorts, established clinical infrastructure, and the ongoing flow of clinical data and biospecimens to answer mechanistic questions that would be difficult, slow, or expensive to launch as a brand-new standalone study. While the parent project can be an interventional clinical trial or a non-interventional clinical study (such as an observational cohort), the application under this FOA must be for an ancillary mechanistic study and cannot propose a new clinical trial as the funded activity.

The funded ancillary work is expected to be tightly linked to the parent clinical project in a way that meaningfully increases the scientific value of that parent effort. In practical terms, NIAMS is looking for studies that use the parent project’s well-characterized participants, protocols, data systems, and sample collection pipelines to conduct deeper mechanistic investigations, such as interrogating disease pathways, immune mechanisms, tissue biology, biomarker dynamics, or other biologic processes relevant to NIAMS mission areas (arthritis and rheumatic diseases, musculoskeletal biology and disorders, and skin biology and diseases). The parent project is expected to already be positioned to provide what the ancillary study needs: access to participants, existing or prospectively collected clinical data, and biological samples (or the ability to collect them during the ongoing study window). Because the opportunity is designed around time sensitivity, the FOA also emphasizes an accelerated review and award process, aiming to move strong applications forward quickly so investigators can capture perishable opportunities tied to the timeline of the ongoing clinical project.

This FOA is essentially a “leverage what already exists” mechanism. NIAMS is trying to maximize return on investment by enabling researchers to build on resources that are already paid for and operational, rather than duplicating recruitment, site setup, and data collection in a separate grant. The intended payoff is a better mechanistic understanding of diseases or organ systems within NIAMS’s portfolio, with the downstream potential to uncover new diagnostic markers, therapeutic targets, or prevention strategies. In other words, NIAMS is not just funding add-on measurements for their own sake; it is funding mechanistic add-ons that can sharpen interpretation of clinical outcomes and expand the translational impact of the parent project.

From an eligibility standpoint, the FOA is broad and includes many types of U.S.-based organizations: state, county, city, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. It also explicitly includes a range of mission-relevant and underserved-serving institution types and community-connected entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, and certain tribal governments and tribal organizations. U.S. territories or possessions are also listed among eligible applicant categories.

At the same time, there are clear limitations related to foreign involvement. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply. However, “foreign components” as defined by NIH policy are allowed, meaning a U.S. applicant may include specific foreign activities or collaborations when justified and consistent with NIH rules, even though the primary applicant organization must be domestic.

Administratively, this is an R01 grant mechanism under the NIH “Health” activity category (CFDA 93.846), and it is labeled “Clinical Trial Not Allowed,” reinforcing that the proposed R01 project itself must not be a clinical trial. The opportunity lists an award ceiling of $300,000 (as provided in the source text) and had an original closing date of December 1, 2020. The overall structure signals that NIAMS wants focused, mechanistically rich ancillary aims that can be completed efficiently by piggybacking on a parent project already in motion, producing interpretable biological insight that complements and elevates the original clinical study.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2019-04-25.
• Applicants must submit their applications by 2020-12-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AR 20 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: